NZ739521A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- NZ739521A NZ739521A NZ739521A NZ73952113A NZ739521A NZ 739521 A NZ739521 A NZ 739521A NZ 739521 A NZ739521 A NZ 739521A NZ 73952113 A NZ73952113 A NZ 73952113A NZ 739521 A NZ739521 A NZ 739521A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical compositions
- treatment
- phenoxy
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| NZ705813A NZ705813A (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer’s disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ739521A true NZ739521A (en) | 2019-06-28 |
Family
ID=49354960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ739521A NZ739521A (en) | 2012-10-05 | 2013-10-02 | Pharmaceutical compositions |
| NZ705813A NZ705813A (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer’s disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ705813A NZ705813A (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer’s disease |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (enExample) |
| JP (2) | JP6566868B2 (enExample) |
| KR (1) | KR20150064743A (enExample) |
| CN (2) | CN104703592A (enExample) |
| AU (2) | AU2013327450B2 (enExample) |
| BR (1) | BR112015007641A8 (enExample) |
| CA (1) | CA2886785C (enExample) |
| EA (1) | EA201590687A1 (enExample) |
| HK (1) | HK1207004A1 (enExample) |
| IL (1) | IL237730B (enExample) |
| IN (1) | IN2015DN03734A (enExample) |
| MX (1) | MX377733B (enExample) |
| NZ (2) | NZ739521A (enExample) |
| SG (2) | SG11201502210VA (enExample) |
| WO (1) | WO2014055588A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114031687B (zh) * | 2021-11-12 | 2022-06-07 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026811A1 (en) * | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201702648YA (en) | 2017-04-27 |
| IL237730B (en) | 2018-10-31 |
| CN104703592A (zh) | 2015-06-10 |
| KR20150064743A (ko) | 2015-06-11 |
| BR112015007641A8 (pt) | 2018-04-03 |
| MX377733B (es) | 2025-03-11 |
| AU2013327450B2 (en) | 2018-07-12 |
| CA2886785C (en) | 2022-06-07 |
| CA2886785A1 (en) | 2014-04-10 |
| JP6566868B2 (ja) | 2019-08-28 |
| MX2015003732A (es) | 2015-09-23 |
| EP2903606A1 (en) | 2015-08-12 |
| BR112015007641A2 (pt) | 2017-07-04 |
| AU2013327450A1 (en) | 2015-05-14 |
| AU2018203434A1 (en) | 2018-06-07 |
| IN2015DN03734A (enExample) | 2015-09-18 |
| HK1207004A1 (zh) | 2016-01-22 |
| WO2014055588A1 (en) | 2014-04-10 |
| JP6894940B2 (ja) | 2021-06-30 |
| JP2015535850A (ja) | 2015-12-17 |
| EA201590687A1 (ru) | 2015-09-30 |
| NZ705813A (en) | 2018-02-23 |
| SG11201502210VA (en) | 2015-04-29 |
| JP2019163301A (ja) | 2019-09-26 |
| CN110292638A (zh) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355409B (es) | Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida. | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| EA201691692A1 (ru) | Терапевтические наночастицы, содержащие терапевтический агент, и способы их изготовления и применения | |
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| NZ628030A (en) | Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
| NZ739521A (en) | Pharmaceutical compositions | |
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| IN2015DN01119A (enExample) | ||
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. | |
| PH12014502567A1 (en) | Piperidine derivatives for gpr119 agonist | |
| PH12015501398A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| PH12015500012B1 (en) | Benzodioxole derivative and preparation method and use thereof | |
| MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| EA201390327A1 (ru) | Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов | |
| MY170643A (en) | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2021 BY CPA GLOBAL Effective date: 20200820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2022 BY CPA GLOBAL Effective date: 20210819 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2023 BY COMPUTER PACKAGES INC Effective date: 20220917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2024 BY COMPUTER PACKAGES INC Effective date: 20230930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2025 BY COMPUTER PACKAGES INC Effective date: 20240917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2026 BY COMPUTER PACKAGES INC Effective date: 20250917 |